Pharmaceutical

Lilly to acquire biopharma firm Versanis for $1.9bn

Eli Lilly and Company has signed an agreement for the acquisition of biopharmaceutical firm Versanis Bio in a deal totalling $1.925bn.

Jul 17, 2023 - 20:00
Lilly to acquire biopharma firm Versanis for $1.9bn
Eli Lilly and Company has signed an agreement for the acquisition of biopharmaceutical firm Versanis Bio in a deal totalling $1.925bn.
Read the original article

Tags:

Previous Article

Korro Bio enters merger deal with Frequency Therapeutics

Next Article

Fighting AMR with a value and subscription model 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Cancer patients shouldn’t be responsible for out-of-pocket costs

Opinion: Cancer patients shouldn’t be responsible for o...

May 23, 2023

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Editas trades part of Vertex CRISPR therapy licencing r...

Oct 6, 2024

Opinion: The staggering financial burden of giving birth — even with insurance

Opinion: The staggering financial burden of giving birt...

Jun 24, 2023